You just read:

Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery

News provided by

Bausch Health Companies Inc.

Sep 05, 2018, 13:38 ET